Sen. Jacqueline Y. Collins
Filed: 5/1/2018
| |||||||
| |||||||
| |||||||
1 | AMENDMENT TO SENATE BILL 2341
| ||||||
2 | AMENDMENT NO. ______. Amend Senate Bill 2341
| ||||||
3 | "Section 5. The Illinois Controlled Substances Act is | ||||||
4 | amended by changing Sections 102 and 204 as follows: | ||||||
5 | (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102) | ||||||
6 | Sec. 102. Definitions. As used in this Act, unless the | ||||||
7 | context
otherwise requires:
| ||||||
8 | (a) "Addict" means any person who habitually uses any drug, | ||||||
9 | chemical,
substance or dangerous drug other than alcohol so as | ||||||
10 | to endanger the public
morals, health, safety or welfare or who | ||||||
11 | is so far addicted to the use of a
dangerous drug or controlled | ||||||
12 | substance other than alcohol as to have lost
the power of self | ||||||
13 | control with reference to his or her addiction.
| ||||||
14 | (b) "Administer" means the direct application of a | ||||||
15 | controlled
substance, whether by injection, inhalation, | ||||||
16 | ingestion, or any other
means, to the body of a patient, |
| |||||||
| |||||||
1 | research subject, or animal (as
defined by the Humane | ||||||
2 | Euthanasia in Animal Shelters Act) by:
| ||||||
3 | (1) a practitioner (or, in his or her presence, by his | ||||||
4 | or her authorized agent),
| ||||||
5 | (2) the patient or research subject pursuant to an | ||||||
6 | order, or
| ||||||
7 | (3) a euthanasia technician as defined by the Humane | ||||||
8 | Euthanasia in
Animal Shelters Act.
| ||||||
9 | (c) "Agent" means an authorized person who acts on behalf | ||||||
10 | of or at
the direction of a manufacturer, distributor, | ||||||
11 | dispenser, prescriber, or practitioner. It does not
include a | ||||||
12 | common or contract carrier, public warehouseman or employee of
| ||||||
13 | the carrier or warehouseman.
| ||||||
14 | (c-1) "Anabolic Steroids" means any drug or hormonal | ||||||
15 | substance,
chemically and pharmacologically related to | ||||||
16 | testosterone (other than
estrogens, progestins, | ||||||
17 | corticosteroids, and dehydroepiandrosterone),
and includes:
| ||||||
18 | (i) 3[beta],17-dihydroxy-5a-androstane, | ||||||
19 | (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, | ||||||
20 | (iii) 5[alpha]-androstan-3,17-dione, | ||||||
21 | (iv) 1-androstenediol (3[beta], | ||||||
22 | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), | ||||||
23 | (v) 1-androstenediol (3[alpha], | ||||||
24 | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), | ||||||
25 | (vi) 4-androstenediol | ||||||
26 | (3[beta],17[beta]-dihydroxy-androst-4-ene), |
| |||||||
| |||||||
1 | (vii) 5-androstenediol | ||||||
2 | (3[beta],17[beta]-dihydroxy-androst-5-ene), | ||||||
3 | (viii) 1-androstenedione | ||||||
4 | ([5alpha]-androst-1-en-3,17-dione), | ||||||
5 | (ix) 4-androstenedione | ||||||
6 | (androst-4-en-3,17-dione), | ||||||
7 | (x) 5-androstenedione | ||||||
8 | (androst-5-en-3,17-dione), | ||||||
9 | (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- | ||||||
10 | hydroxyandrost-4-en-3-one), | ||||||
11 | (xii) boldenone (17[beta]-hydroxyandrost- | ||||||
12 | 1,4,-diene-3-one), | ||||||
13 | (xiii) boldione (androsta-1,4- | ||||||
14 | diene-3,17-dione), | ||||||
15 | (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 | ||||||
16 | [beta]-hydroxyandrost-4-en-3-one), | ||||||
17 | (xv) clostebol (4-chloro-17[beta]- | ||||||
18 | hydroxyandrost-4-en-3-one), | ||||||
19 | (xvi) dehydrochloromethyltestosterone (4-chloro- | ||||||
20 | 17[beta]-hydroxy-17[alpha]-methyl- | ||||||
21 | androst-1,4-dien-3-one), | ||||||
22 | (xvii) desoxymethyltestosterone | ||||||
23 | (17[alpha]-methyl-5[alpha] | ||||||
24 | -androst-2-en-17[beta]-ol)(a.k.a., madol), | ||||||
25 | (xviii) [delta]1-dihydrotestosterone (a.k.a. | ||||||
26 | '1-testosterone') (17[beta]-hydroxy- |
| |||||||
| |||||||
1 | 5[alpha]-androst-1-en-3-one), | ||||||
2 | (xix) 4-dihydrotestosterone (17[beta]-hydroxy- | ||||||
3 | androstan-3-one), | ||||||
4 | (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- | ||||||
5 | 5[alpha]-androstan-3-one), | ||||||
6 | (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- | ||||||
7 | hydroxyestr-4-ene), | ||||||
8 | (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- | ||||||
9 | 1[beta],17[beta]-dihydroxyandrost-4-en-3-one), | ||||||
10 | (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], | ||||||
11 | 17[beta]-dihydroxyandrost-1,4-dien-3-one), | ||||||
12 | (xxiv) furazabol (17[alpha]-methyl-17[beta]- | ||||||
13 | hydroxyandrostano[2,3-c]-furazan), | ||||||
14 | (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one , ) | ||||||
15 | (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- | ||||||
16 | androst-4-en-3-one), | ||||||
17 | (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- | ||||||
18 | dihydroxy-estr-4-en-3-one), | ||||||
19 | (xxviii) mestanolone (17[alpha]-methyl-17[beta]- | ||||||
20 | hydroxy-5-androstan-3-one), | ||||||
21 | (xxix) mesterolone (1amethyl-17[beta]-hydroxy- | ||||||
22 | [5a]-androstan-3-one), | ||||||
23 | (xxx) methandienone (17[alpha]-methyl-17[beta]- | ||||||
24 | hydroxyandrost-1,4-dien-3-one), | ||||||
25 | (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- | ||||||
26 | dihydroxyandrost-5-ene), |
| |||||||
| |||||||
1 | (xxxii) methenolone (1-methyl-17[beta]-hydroxy- | ||||||
2 | 5[alpha]-androst-1-en-3-one), | ||||||
3 | (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- | ||||||
4 | dihydroxy-5a-androstane ) , | ||||||
5 | (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy | ||||||
6 | -5a-androstane ) , | ||||||
7 | (xxxv) 17[alpha]-methyl-3[beta],17[beta]- | ||||||
8 | dihydroxyandrost-4-ene), | ||||||
9 | (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- | ||||||
10 | methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), | ||||||
11 | (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- | ||||||
12 | hydroxyestra-4,9(10)-dien-3-one), | ||||||
13 | (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- | ||||||
14 | hydroxyestra-4,9-11-trien-3-one), | ||||||
15 | (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- | ||||||
16 | hydroxyandrost-4-en-3-one), | ||||||
17 | (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- | ||||||
18 | hydroxyestr-4-en-3-one), | ||||||
19 | (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone | ||||||
20 | (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- | ||||||
21 | androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- | ||||||
22 | 1-testosterone'), | ||||||
23 | (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), | ||||||
24 | (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- | ||||||
25 | dihydroxyestr-4-ene), | ||||||
26 | (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- |
| |||||||
| |||||||
1 | dihydroxyestr-4-ene), | ||||||
2 | (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- | ||||||
3 | dihydroxyestr-5-ene), | ||||||
4 | (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- | ||||||
5 | dihydroxyestr-5-ene), | ||||||
6 | (xlvii) 19-nor-4,9(10)-androstadienedione | ||||||
7 | (estra-4,9(10)-diene-3,17-dione), | ||||||
8 | (xlviii) 19-nor-4-androstenedione (estr-4- | ||||||
9 | en-3,17-dione), | ||||||
10 | (xlix) 19-nor-5-androstenedione (estr-5- | ||||||
11 | en-3,17-dione), | ||||||
12 | (l) norbolethone (13[beta], 17a-diethyl-17[beta]- | ||||||
13 | hydroxygon-4-en-3-one), | ||||||
14 | (li) norclostebol (4-chloro-17[beta]- | ||||||
15 | hydroxyestr-4-en-3-one), | ||||||
16 | (lii) norethandrolone (17[alpha]-ethyl-17[beta]- | ||||||
17 | hydroxyestr-4-en-3-one), | ||||||
18 | (liii) normethandrolone (17[alpha]-methyl-17[beta]- | ||||||
19 | hydroxyestr-4-en-3-one), | ||||||
20 | (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- | ||||||
21 | 2-oxa-5[alpha]-androstan-3-one), | ||||||
22 | (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- | ||||||
23 | dihydroxyandrost-4-en-3-one), | ||||||
24 | (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- | ||||||
25 | 17[beta]-hydroxy-(5[alpha]-androstan-3-one), | ||||||
26 | (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- |
| |||||||
| |||||||
1 | (5[alpha]-androst-2-eno[3,2-c]-pyrazole), | ||||||
2 | (lviii) stenbolone (17[beta]-hydroxy-2-methyl- | ||||||
3 | (5[alpha]-androst-1-en-3-one), | ||||||
4 | (lix) testolactone (13-hydroxy-3-oxo-13,17- | ||||||
5 | secoandrosta-1,4-dien-17-oic | ||||||
6 | acid lactone), | ||||||
7 | (lx) testosterone (17[beta]-hydroxyandrost- | ||||||
8 | 4-en-3-one), | ||||||
9 | (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- | ||||||
10 | diethyl-17[beta]-hydroxygon- | ||||||
11 | 4,9,11-trien-3-one), | ||||||
12 | (lxii) trenbolone (17[beta]-hydroxyestr-4,9, | ||||||
13 | 11-trien-3-one).
| ||||||
14 | Any person who is otherwise lawfully in possession of an | ||||||
15 | anabolic
steroid, or who otherwise lawfully manufactures, | ||||||
16 | distributes, dispenses,
delivers, or possesses with intent to | ||||||
17 | deliver an anabolic steroid, which
anabolic steroid is | ||||||
18 | expressly intended for and lawfully allowed to be
administered | ||||||
19 | through implants to livestock or other nonhuman species, and
| ||||||
20 | which is approved by the Secretary of Health and Human Services | ||||||
21 | for such
administration, and which the person intends to | ||||||
22 | administer or have
administered through such implants, shall | ||||||
23 | not be considered to be in
unauthorized possession or to | ||||||
24 | unlawfully manufacture, distribute, dispense,
deliver, or | ||||||
25 | possess with intent to deliver such anabolic steroid for
| ||||||
26 | purposes of this Act.
|
| |||||||
| |||||||
1 | (d) "Administration" means the Drug Enforcement | ||||||
2 | Administration,
United States Department of Justice, or its | ||||||
3 | successor agency.
| ||||||
4 | (d-5) "Clinical Director, Prescription Monitoring Program" | ||||||
5 | means a Department of Human Services administrative employee | ||||||
6 | licensed to either prescribe or dispense controlled substances | ||||||
7 | who shall run the clinical aspects of the Department of Human | ||||||
8 | Services Prescription Monitoring Program and its Prescription | ||||||
9 | Information Library. | ||||||
10 | (d-10) "Compounding" means the preparation and mixing of | ||||||
11 | components, excluding flavorings, (1) as the result of a | ||||||
12 | prescriber's prescription drug order or initiative based on the | ||||||
13 | prescriber-patient-pharmacist relationship in the course of | ||||||
14 | professional practice or (2) for the purpose of, or incident | ||||||
15 | to, research, teaching, or chemical analysis and not for sale | ||||||
16 | or dispensing. "Compounding" includes the preparation of drugs | ||||||
17 | or devices in anticipation of receiving prescription drug | ||||||
18 | orders based on routine, regularly observed dispensing | ||||||
19 | patterns. Commercially available products may be compounded | ||||||
20 | for dispensing to individual patients only if both of the | ||||||
21 | following conditions are met: (i) the commercial product is not | ||||||
22 | reasonably available from normal distribution channels in a | ||||||
23 | timely manner to meet the patient's needs and (ii) the | ||||||
24 | prescribing practitioner has requested that the drug be | ||||||
25 | compounded. | ||||||
26 | (e) "Control" means to add a drug or other substance, or |
| |||||||
| |||||||
1 | immediate
precursor, to a Schedule whether by
transfer from | ||||||
2 | another Schedule or otherwise.
| ||||||
3 | (f) "Controlled Substance" means (i) a drug, substance, | ||||||
4 | immediate
precursor, or synthetic drug in the Schedules of | ||||||
5 | Article II of this Act or (ii) a drug or other substance, or | ||||||
6 | immediate precursor, designated as a controlled substance by | ||||||
7 | the Department through administrative rule. The term does not | ||||||
8 | include distilled spirits, wine, malt beverages, or tobacco, as | ||||||
9 | those terms are
defined or used in the Liquor Control Act of | ||||||
10 | 1934 and the Tobacco Products Tax
Act of 1995.
| ||||||
11 | (f-5) "Controlled substance analog" means a substance: | ||||||
12 | (1) the chemical structure of which is substantially | ||||||
13 | similar to the chemical structure of a controlled substance | ||||||
14 | in Schedule I or II; | ||||||
15 | (2) which has a stimulant, depressant, or | ||||||
16 | hallucinogenic effect on the central nervous system that is | ||||||
17 | substantially similar to or greater than the stimulant, | ||||||
18 | depressant, or hallucinogenic effect on the central | ||||||
19 | nervous system of a controlled substance in Schedule I or | ||||||
20 | II; or | ||||||
21 | (3) with respect to a particular person, which such | ||||||
22 | person represents or intends to have a stimulant, | ||||||
23 | depressant, or hallucinogenic effect on the central | ||||||
24 | nervous system that is substantially similar to or greater | ||||||
25 | than the stimulant, depressant, or hallucinogenic effect | ||||||
26 | on the central nervous system of a controlled substance in |
| |||||||
| |||||||
1 | Schedule I or II. | ||||||
2 | (g) "Counterfeit substance" means a controlled substance, | ||||||
3 | which, or
the container or labeling of which, without | ||||||
4 | authorization bears the
trademark, trade name, or other | ||||||
5 | identifying mark, imprint, number or
device, or any likeness | ||||||
6 | thereof, of a manufacturer, distributor, or
dispenser other | ||||||
7 | than the person who in fact manufactured, distributed,
or | ||||||
8 | dispensed the substance.
| ||||||
9 | (h) "Deliver" or "delivery" means the actual, constructive | ||||||
10 | or
attempted transfer of possession of a controlled substance, | ||||||
11 | with or
without consideration, whether or not there is an | ||||||
12 | agency relationship.
| ||||||
13 | (i) "Department" means the Illinois Department of Human | ||||||
14 | Services (as
successor to the Department of Alcoholism and | ||||||
15 | Substance Abuse) or its successor agency.
| ||||||
16 | (j) (Blank).
| ||||||
17 | (k) "Department of Corrections" means the Department of | ||||||
18 | Corrections
of the State of Illinois or its successor agency.
| ||||||
19 | (l) "Department of Financial and Professional Regulation" | ||||||
20 | means the Department
of Financial and Professional Regulation | ||||||
21 | of the State of Illinois or its successor agency.
| ||||||
22 | (m) "Depressant" means any drug that (i) causes an overall | ||||||
23 | depression of central nervous system functions, (ii) causes | ||||||
24 | impaired consciousness and awareness, and (iii) can be | ||||||
25 | habit-forming or lead to a substance abuse problem, including | ||||||
26 | but not limited to alcohol, cannabis and its active principles |
| |||||||
| |||||||
1 | and their analogs, benzodiazepines and their analogs, | ||||||
2 | barbiturates and their analogs, opioids (natural and | ||||||
3 | synthetic) and their analogs, and chloral hydrate and similar | ||||||
4 | sedative hypnotics.
| ||||||
5 | (n) (Blank).
| ||||||
6 | (o) "Director" means the Director of the Illinois State | ||||||
7 | Police or his or her designated agents.
| ||||||
8 | (p) "Dispense" means to deliver a controlled substance to | ||||||
9 | an
ultimate user or research subject by or pursuant to the | ||||||
10 | lawful order of
a prescriber, including the prescribing, | ||||||
11 | administering, packaging,
labeling, or compounding necessary | ||||||
12 | to prepare the substance for that
delivery.
| ||||||
13 | (q) "Dispenser" means a practitioner who dispenses.
| ||||||
14 | (r) "Distribute" means to deliver, other than by | ||||||
15 | administering or
dispensing, a controlled substance.
| ||||||
16 | (s) "Distributor" means a person who distributes.
| ||||||
17 | (t) "Drug" means (1) substances recognized as drugs in the | ||||||
18 | official
United States Pharmacopoeia, Official Homeopathic | ||||||
19 | Pharmacopoeia of the
United States, or official National | ||||||
20 | Formulary, or any supplement to any
of them; (2) substances | ||||||
21 | intended for use in diagnosis, cure, mitigation,
treatment, or | ||||||
22 | prevention of disease in man or animals; (3) substances
(other | ||||||
23 | than food) intended to affect the structure of any function of
| ||||||
24 | the body of man or animals and (4) substances intended for use | ||||||
25 | as a
component of any article specified in clause (1), (2), or | ||||||
26 | (3) of this
subsection. It does not include devices or their |
| |||||||
| |||||||
1 | components, parts, or
accessories.
| ||||||
2 | (t-3) "Electronic health record" or "EHR" means an | ||||||
3 | electronic record of health-related information on an | ||||||
4 | individual that is created, gathered, managed, and consulted by | ||||||
5 | authorized health care clinicians and staff. | ||||||
6 | (t-4) "Emergency medical services personnel" has the | ||||||
7 | meaning ascribed to it in the Emergency Medical Services (EMS) | ||||||
8 | Systems Act. | ||||||
9 | (t-5) "Euthanasia agency" means
an entity certified by the | ||||||
10 | Department of Financial and Professional Regulation for the
| ||||||
11 | purpose of animal euthanasia that holds an animal control | ||||||
12 | facility license or
animal
shelter license under the Animal | ||||||
13 | Welfare Act. A euthanasia agency is
authorized to purchase, | ||||||
14 | store, possess, and utilize Schedule II nonnarcotic and
| ||||||
15 | Schedule III nonnarcotic drugs for the sole purpose of animal | ||||||
16 | euthanasia.
| ||||||
17 | (t-10) "Euthanasia drugs" means Schedule II or Schedule III | ||||||
18 | substances
(nonnarcotic controlled substances) that are used | ||||||
19 | by a euthanasia agency for
the purpose of animal euthanasia.
| ||||||
20 | (u) "Good faith" means the prescribing or dispensing of a | ||||||
21 | controlled
substance by a practitioner in the regular course of | ||||||
22 | professional
treatment to or for any person who is under his or | ||||||
23 | her treatment for a
pathology or condition other than that | ||||||
24 | individual's physical or
psychological dependence upon or | ||||||
25 | addiction to a controlled substance,
except as provided herein: | ||||||
26 | and application of the term to a pharmacist
shall mean the |
| |||||||
| |||||||
1 | dispensing of a controlled substance pursuant to the
| ||||||
2 | prescriber's order which in the professional judgment of the | ||||||
3 | pharmacist
is lawful. The pharmacist shall be guided by | ||||||
4 | accepted professional
standards including, but not limited to | ||||||
5 | the following, in making the
judgment:
| ||||||
6 | (1) lack of consistency of prescriber-patient | ||||||
7 | relationship,
| ||||||
8 | (2) frequency of prescriptions for same drug by one | ||||||
9 | prescriber for
large numbers of patients,
| ||||||
10 | (3) quantities beyond those normally prescribed,
| ||||||
11 | (4) unusual dosages (recognizing that there may be | ||||||
12 | clinical circumstances where more or less than the usual | ||||||
13 | dose may be used legitimately),
| ||||||
14 | (5) unusual geographic distances between patient, | ||||||
15 | pharmacist and
prescriber,
| ||||||
16 | (6) consistent prescribing of habit-forming drugs.
| ||||||
17 | (u-0.5) "Hallucinogen" means a drug that causes markedly | ||||||
18 | altered sensory perception leading to hallucinations of any | ||||||
19 | type. | ||||||
20 | (u-1) "Home infusion services" means services provided by a | ||||||
21 | pharmacy in
compounding solutions for direct administration to | ||||||
22 | a patient in a private
residence, long-term care facility, or | ||||||
23 | hospice setting by means of parenteral,
intravenous, | ||||||
24 | intramuscular, subcutaneous, or intraspinal infusion.
| ||||||
25 | (u-5) "Illinois State Police" means the State
Police of the | ||||||
26 | State of Illinois, or its successor agency. |
| |||||||
| |||||||
1 | (v) "Immediate precursor" means a substance:
| ||||||
2 | (1) which the Department has found to be and by rule | ||||||
3 | designated as
being a principal compound used, or produced | ||||||
4 | primarily for use, in the
manufacture of a controlled | ||||||
5 | substance;
| ||||||
6 | (2) which is an immediate chemical intermediary used or | ||||||
7 | likely to
be used in the manufacture of such controlled | ||||||
8 | substance; and
| ||||||
9 | (3) the control of which is necessary to prevent, | ||||||
10 | curtail or limit
the manufacture of such controlled | ||||||
11 | substance.
| ||||||
12 | (w) "Instructional activities" means the acts of teaching, | ||||||
13 | educating
or instructing by practitioners using controlled | ||||||
14 | substances within
educational facilities approved by the State | ||||||
15 | Board of Education or
its successor agency.
| ||||||
16 | (x) "Local authorities" means a duly organized State, | ||||||
17 | County or
Municipal peace unit or police force.
| ||||||
18 | (y) "Look-alike substance" means a substance, other than a | ||||||
19 | controlled
substance which (1) by overall dosage unit | ||||||
20 | appearance, including shape,
color, size, markings or lack | ||||||
21 | thereof, taste, consistency, or any other
identifying physical | ||||||
22 | characteristic of the substance, would lead a reasonable
person | ||||||
23 | to believe that the substance is a controlled substance, or (2) | ||||||
24 | is
expressly or impliedly represented to be a controlled | ||||||
25 | substance or is
distributed under circumstances which would | ||||||
26 | lead a reasonable person to
believe that the substance is a |
| |||||||
| |||||||
1 | controlled substance. For the purpose of
determining whether | ||||||
2 | the representations made or the circumstances of the
| ||||||
3 | distribution would lead a reasonable person to believe the | ||||||
4 | substance to be
a controlled substance under this clause (2) of | ||||||
5 | subsection (y), the court or
other authority may consider the | ||||||
6 | following factors in addition to any other
factor that may be | ||||||
7 | relevant:
| ||||||
8 | (a) statements made by the owner or person in control | ||||||
9 | of the substance
concerning its nature, use or effect;
| ||||||
10 | (b) statements made to the buyer or recipient that the | ||||||
11 | substance may
be resold for profit;
| ||||||
12 | (c) whether the substance is packaged in a manner | ||||||
13 | normally used for the
illegal distribution of controlled | ||||||
14 | substances;
| ||||||
15 | (d) whether the distribution or attempted distribution | ||||||
16 | included an
exchange of or demand for money or other | ||||||
17 | property as consideration, and
whether the amount of the | ||||||
18 | consideration was substantially greater than the
| ||||||
19 | reasonable retail market value of the substance.
| ||||||
20 | Clause (1) of this subsection (y) shall not apply to a | ||||||
21 | noncontrolled
substance in its finished dosage form that was | ||||||
22 | initially introduced into
commerce prior to the initial | ||||||
23 | introduction into commerce of a controlled
substance in its | ||||||
24 | finished dosage form which it may substantially resemble.
| ||||||
25 | Nothing in this subsection (y) prohibits the dispensing or | ||||||
26 | distributing
of noncontrolled substances by persons authorized |
| |||||||
| |||||||
1 | to dispense and
distribute controlled substances under this | ||||||
2 | Act, provided that such action
would be deemed to be carried | ||||||
3 | out in good faith under subsection (u) if the
substances | ||||||
4 | involved were controlled substances.
| ||||||
5 | Nothing in this subsection (y) or in this Act prohibits the | ||||||
6 | manufacture,
preparation, propagation, compounding, | ||||||
7 | processing, packaging, advertising
or distribution of a drug or | ||||||
8 | drugs by any person registered pursuant to
Section 510 of the | ||||||
9 | Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
| ||||||
10 | (y-1) "Mail-order pharmacy" means a pharmacy that is | ||||||
11 | located in a state
of the United States that delivers, | ||||||
12 | dispenses or
distributes, through the United States Postal | ||||||
13 | Service or other common
carrier, to Illinois residents, any | ||||||
14 | substance which requires a prescription.
| ||||||
15 | (z) "Manufacture" means the production, preparation, | ||||||
16 | propagation,
compounding, conversion or processing of a | ||||||
17 | controlled substance other than methamphetamine, either
| ||||||
18 | directly or indirectly, by extraction from substances of | ||||||
19 | natural origin,
or independently by means of chemical | ||||||
20 | synthesis, or by a combination of
extraction and chemical | ||||||
21 | synthesis, and includes any packaging or
repackaging of the | ||||||
22 | substance or labeling of its container, except that
this term | ||||||
23 | does not include:
| ||||||
24 | (1) by an ultimate user, the preparation or compounding | ||||||
25 | of a
controlled substance for his or her own use; or
| ||||||
26 | (2) by a practitioner, or his or her authorized agent |
| |||||||
| |||||||
1 | under his or her
supervision, the preparation, | ||||||
2 | compounding, packaging, or labeling of a
controlled | ||||||
3 | substance:
| ||||||
4 | (a) as an incident to his or her administering or | ||||||
5 | dispensing of a
controlled substance in the course of | ||||||
6 | his or her professional practice; or
| ||||||
7 | (b) as an incident to lawful research, teaching or | ||||||
8 | chemical
analysis and not for sale.
| ||||||
9 | (z-1) (Blank).
| ||||||
10 | (z-5) "Medication shopping" means the conduct prohibited | ||||||
11 | under subsection (a) of Section 314.5 of this Act. | ||||||
12 | (z-10) "Mid-level practitioner" means (i) a physician | ||||||
13 | assistant who has been delegated authority to prescribe through | ||||||
14 | a written delegation of authority by a physician licensed to | ||||||
15 | practice medicine in all of its branches, in accordance with | ||||||
16 | Section 7.5 of the Physician Assistant Practice Act of 1987, | ||||||
17 | (ii) an advanced practice registered nurse who has been | ||||||
18 | delegated authority to prescribe through a written delegation | ||||||
19 | of authority by a physician licensed to practice medicine in | ||||||
20 | all of its branches or by a podiatric physician, in accordance | ||||||
21 | with Section 65-40 of the Nurse Practice Act, (iii) an advanced | ||||||
22 | practice registered nurse certified as a nurse practitioner, | ||||||
23 | nurse midwife, or clinical nurse specialist who has been | ||||||
24 | granted authority to prescribe by a hospital affiliate in | ||||||
25 | accordance with Section 65-45 of the Nurse Practice Act, (iv) | ||||||
26 | an animal euthanasia agency, or (v) a prescribing psychologist. |
| |||||||
| |||||||
1 | (aa) "Narcotic drug" means any of the following, whether | ||||||
2 | produced
directly or indirectly by extraction from substances | ||||||
3 | of vegetable origin,
or independently by means of chemical | ||||||
4 | synthesis, or by a combination of
extraction and chemical | ||||||
5 | synthesis:
| ||||||
6 | (1) opium, opiates, derivatives of opium and opiates, | ||||||
7 | including their isomers, esters, ethers, salts, and salts | ||||||
8 | of isomers, esters, and ethers, whenever the existence of | ||||||
9 | such isomers, esters, ethers, and salts is possible within | ||||||
10 | the specific chemical designation; however the term | ||||||
11 | "narcotic drug" does not include the isoquinoline | ||||||
12 | alkaloids of opium;
| ||||||
13 | (2) (blank);
| ||||||
14 | (3) opium poppy and poppy straw;
| ||||||
15 | (4) coca leaves, except coca leaves and extracts of | ||||||
16 | coca leaves from which substantially all of the cocaine and | ||||||
17 | ecgonine, and their isomers, derivatives and salts, have | ||||||
18 | been removed;
| ||||||
19 | (5) cocaine, its salts, optical and geometric isomers, | ||||||
20 | and salts of isomers; | ||||||
21 | (6) ecgonine, its derivatives, their salts, isomers, | ||||||
22 | and salts of isomers; | ||||||
23 | (7) any compound, mixture, or preparation which | ||||||
24 | contains any quantity of any of the substances referred to | ||||||
25 | in subparagraphs (1) through (6). | ||||||
26 | (bb) "Nurse" means a registered nurse licensed under the
|
| |||||||
| |||||||
1 | Nurse Practice Act.
| ||||||
2 | (cc) (Blank).
| ||||||
3 | (dd) "Opiate" means any substance having an addiction | ||||||
4 | forming or
addiction sustaining liability similar to morphine | ||||||
5 | or being capable of
conversion into a drug having addiction | ||||||
6 | forming or addiction sustaining
liability.
| ||||||
7 | (ee) "Opium poppy" means the plant of the species Papaver
| ||||||
8 | somniferum L., except its seeds.
| ||||||
9 | (ee-5) "Oral dosage" means a tablet, capsule, elixir, or | ||||||
10 | solution or other liquid form of medication intended for | ||||||
11 | administration by mouth, but the term does not include a form | ||||||
12 | of medication intended for buccal, sublingual, or transmucosal | ||||||
13 | administration. | ||||||
14 | (ff) "Parole and Pardon Board" means the Parole and Pardon | ||||||
15 | Board of
the State of Illinois or its successor agency.
| ||||||
16 | (gg) "Person" means any individual, corporation, | ||||||
17 | mail-order pharmacy,
government or governmental subdivision or | ||||||
18 | agency, business trust, estate,
trust, partnership or | ||||||
19 | association, or any other entity.
| ||||||
20 | (hh) "Pharmacist" means any person who holds a license or | ||||||
21 | certificate of
registration as a registered pharmacist, a local | ||||||
22 | registered pharmacist
or a registered assistant pharmacist | ||||||
23 | under the Pharmacy Practice Act.
| ||||||
24 | (ii) "Pharmacy" means any store, ship or other place in | ||||||
25 | which
pharmacy is authorized to be practiced under the Pharmacy | ||||||
26 | Practice Act.
|
| |||||||
| |||||||
1 | (ii-5) "Pharmacy shopping" means the conduct prohibited | ||||||
2 | under subsection (b) of Section 314.5 of this Act. | ||||||
3 | (ii-10) "Physician" (except when the context otherwise | ||||||
4 | requires) means a person licensed to practice medicine in all | ||||||
5 | of its branches. | ||||||
6 | (jj) "Poppy straw" means all parts, except the seeds, of | ||||||
7 | the opium
poppy, after mowing.
| ||||||
8 | (kk) "Practitioner" means a physician licensed to practice | ||||||
9 | medicine in all
its branches, dentist, optometrist, podiatric | ||||||
10 | physician,
veterinarian, scientific investigator, pharmacist, | ||||||
11 | physician assistant,
advanced practice registered nurse,
| ||||||
12 | licensed practical
nurse, registered nurse, emergency medical | ||||||
13 | services personnel, hospital, laboratory, or pharmacy, or | ||||||
14 | other
person licensed, registered, or otherwise lawfully | ||||||
15 | permitted by the
United States or this State to distribute, | ||||||
16 | dispense, conduct research
with respect to, administer or use | ||||||
17 | in teaching or chemical analysis, a
controlled substance in the | ||||||
18 | course of professional practice or research.
| ||||||
19 | (ll) "Pre-printed prescription" means a written | ||||||
20 | prescription upon which
the designated drug has been indicated | ||||||
21 | prior to the time of issuance; the term does not mean a written | ||||||
22 | prescription that is individually generated by machine or | ||||||
23 | computer in the prescriber's office.
| ||||||
24 | (mm) "Prescriber" means a physician licensed to practice | ||||||
25 | medicine in all
its branches, dentist, optometrist, | ||||||
26 | prescribing psychologist licensed under Section 4.2 of the |
| |||||||
| |||||||
1 | Clinical Psychologist Licensing Act with prescriptive | ||||||
2 | authority delegated under Section 4.3 of the Clinical | ||||||
3 | Psychologist Licensing Act, podiatric physician, or
| ||||||
4 | veterinarian who issues a prescription, a physician assistant | ||||||
5 | who
issues a
prescription for a controlled substance
in | ||||||
6 | accordance
with Section 303.05, a written delegation, and a | ||||||
7 | written collaborative agreement required under Section 7.5
of | ||||||
8 | the
Physician Assistant Practice Act of 1987, an advanced | ||||||
9 | practice registered
nurse with prescriptive authority | ||||||
10 | delegated under Section 65-40 of the Nurse Practice Act and in | ||||||
11 | accordance with Section 303.05, a written delegation,
and a | ||||||
12 | written
collaborative agreement under Section 65-35 of the | ||||||
13 | Nurse Practice Act, an advanced practice registered nurse | ||||||
14 | certified as a nurse practitioner, nurse midwife, or clinical | ||||||
15 | nurse specialist who has been granted authority to prescribe by | ||||||
16 | a hospital affiliate in accordance with Section 65-45 of the | ||||||
17 | Nurse Practice Act and in accordance with Section 303.05, or an | ||||||
18 | advanced practice registered nurse certified as a nurse | ||||||
19 | practitioner, nurse midwife, or clinical nurse specialist who | ||||||
20 | has full practice authority pursuant to Section 65-43 of the | ||||||
21 | Nurse Practice Act.
| ||||||
22 | (nn) "Prescription" means a written, facsimile, or oral | ||||||
23 | order, or an electronic order that complies with applicable | ||||||
24 | federal requirements,
of
a physician licensed to practice | ||||||
25 | medicine in all its branches,
dentist, podiatric physician or | ||||||
26 | veterinarian for any controlled
substance, of an optometrist in |
| |||||||
| |||||||
1 | accordance with Section 15.1 of the Illinois Optometric | ||||||
2 | Practice Act of 1987, of a prescribing psychologist licensed | ||||||
3 | under Section 4.2 of the Clinical Psychologist Licensing Act | ||||||
4 | with prescriptive authority delegated under Section 4.3 of the | ||||||
5 | Clinical Psychologist Licensing Act, of a physician assistant | ||||||
6 | for a
controlled substance
in accordance with Section 303.05, a | ||||||
7 | written delegation, and a written collaborative agreement | ||||||
8 | required under
Section 7.5 of the
Physician Assistant Practice | ||||||
9 | Act of 1987, of an advanced practice registered
nurse with | ||||||
10 | prescriptive authority delegated under Section 65-40 of the | ||||||
11 | Nurse Practice Act who issues a prescription for a
controlled | ||||||
12 | substance in accordance
with
Section 303.05, a written | ||||||
13 | delegation, and a written collaborative agreement under | ||||||
14 | Section 65-35 of the Nurse Practice Act, of an advanced | ||||||
15 | practice registered nurse certified as a nurse practitioner, | ||||||
16 | nurse midwife, or clinical nurse specialist who has been | ||||||
17 | granted authority to prescribe by a hospital affiliate in | ||||||
18 | accordance with Section 65-45 of the Nurse Practice Act and in | ||||||
19 | accordance with Section 303.05 when required by law, or of an | ||||||
20 | advanced practice registered nurse certified as a nurse | ||||||
21 | practitioner, nurse midwife, or clinical nurse specialist who | ||||||
22 | has full practice authority pursuant to Section 65-43 of the | ||||||
23 | Nurse Practice Act.
| ||||||
24 | (nn-5) "Prescription Information Library" (PIL) means an | ||||||
25 | electronic library that contains reported controlled substance | ||||||
26 | data. |
| |||||||
| |||||||
1 | (nn-10) "Prescription Monitoring Program" (PMP) means the | ||||||
2 | entity that collects, tracks, and stores reported data on | ||||||
3 | controlled substances and select drugs pursuant to Section 316. | ||||||
4 | (oo) "Production" or "produce" means manufacture, | ||||||
5 | planting,
cultivating, growing, or harvesting of a controlled | ||||||
6 | substance other than methamphetamine.
| ||||||
7 | (pp) "Registrant" means every person who is required to | ||||||
8 | register
under Section 302 of this Act.
| ||||||
9 | (qq) "Registry number" means the number assigned to each | ||||||
10 | person
authorized to handle controlled substances under the | ||||||
11 | laws of the United
States and of this State.
| ||||||
12 | (qq-5) "Secretary" means, as the context requires, either | ||||||
13 | the Secretary of the Department or the Secretary of the | ||||||
14 | Department of Financial and Professional Regulation, and the | ||||||
15 | Secretary's designated agents. | ||||||
16 | (rr) "State" includes the State of Illinois and any state, | ||||||
17 | district,
commonwealth, territory, insular possession thereof, | ||||||
18 | and any area
subject to the legal authority of the United | ||||||
19 | States of America.
| ||||||
20 | (rr-5) "Stimulant" means any drug that (i) causes an | ||||||
21 | overall excitation of central nervous system functions, (ii) | ||||||
22 | causes impaired consciousness and awareness, and (iii) can be | ||||||
23 | habit-forming or lead to a substance abuse problem, including | ||||||
24 | but not limited to amphetamines and their analogs, | ||||||
25 | methylphenidate and its analogs, cocaine, and phencyclidine | ||||||
26 | and its analogs. |
| |||||||
| |||||||
1 | (rr-10) "Synthetic drug" includes, but is not limited to, | ||||||
2 | any synthetic cannabinoids or piperazines or any synthetic | ||||||
3 | cathinones as provided for in Schedule I. | ||||||
4 | (ss) "Ultimate user" means a person who lawfully possesses | ||||||
5 | a
controlled substance for his or her own use or for the use of | ||||||
6 | a member of his or her
household or for administering to an | ||||||
7 | animal owned by him or her or by a member
of his or her | ||||||
8 | household.
| ||||||
9 | (Source: P.A. 99-78, eff. 7-20-15; 99-173, eff. 7-29-15; | ||||||
10 | 99-371, eff. 1-1-16; 99-480, eff. 9-9-15; 99-642, eff. 7-28-16; | ||||||
11 | 100-280, eff. 1-1-18; 100-453, eff. 8-25-17; 100-513, eff. | ||||||
12 | 1-1-18; revised 10-6-17.)
| ||||||
13 | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | ||||||
14 | Sec. 204. (a) The controlled substances listed in this | ||||||
15 | Section are
included in Schedule I. | ||||||
16 | (b) Unless specifically excepted or unless listed in | ||||||
17 | another
schedule, any of the following opiates, including their | ||||||
18 | isomers,
esters, ethers, salts, and salts of isomers, esters, | ||||||
19 | and ethers,
whenever the existence of such isomers, esters, | ||||||
20 | ethers and salts is
possible within the specific chemical | ||||||
21 | designation: | ||||||
22 | (1) Acetylmethadol; | ||||||
23 | (1.1) Acetyl-alpha-methylfentanyl | ||||||
24 | (N-[1-(1-methyl-2-phenethyl)-
| ||||||
25 | 4-piperidinyl]-N-phenylacetamide); |
| |||||||
| |||||||
1 | (2) Allylprodine; | ||||||
2 | (3) Alphacetylmethadol, except
| ||||||
3 | levo-alphacetylmethadol (also known as levo-alpha-
| ||||||
4 | acetylmethadol, levomethadyl acetate, or LAAM); | ||||||
5 | (4) Alphameprodine; | ||||||
6 | (5) Alphamethadol; | ||||||
7 | (6) Alpha-methylfentanyl
| ||||||
8 | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
| ||||||
9 | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| ||||||
10 | propanilido) piperidine; | ||||||
11 | (6.1) Alpha-methylthiofentanyl
| ||||||
12 | (N-[1-methyl-2-(2-thienyl)ethyl-
| ||||||
13 | 4-piperidinyl]-N-phenylpropanamide); | ||||||
14 | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | ||||||
15 | (7.1) PEPAP
| ||||||
16 | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | ||||||
17 | (8) Benzethidine; | ||||||
18 | (9) Betacetylmethadol; | ||||||
19 | (9.1) Beta-hydroxyfentanyl
| ||||||
20 | (N-[1-(2-hydroxy-2-phenethyl)-
| ||||||
21 | 4-piperidinyl]-N-phenylpropanamide); | ||||||
22 | (10) Betameprodine; | ||||||
23 | (11) Betamethadol; | ||||||
24 | (12) Betaprodine; | ||||||
25 | (13) Clonitazene; | ||||||
26 | (14) Dextromoramide; |
| |||||||
| |||||||
1 | (15) Diampromide; | ||||||
2 | (16) Diethylthiambutene; | ||||||
3 | (17) Difenoxin; | ||||||
4 | (18) Dimenoxadol; | ||||||
5 | (19) Dimepheptanol; | ||||||
6 | (20) Dimethylthiambutene; | ||||||
7 | (21) Dioxaphetylbutyrate; | ||||||
8 | (22) Dipipanone; | ||||||
9 | (23) Ethylmethylthiambutene; | ||||||
10 | (24) Etonitazene; | ||||||
11 | (25) Etoxeridine; | ||||||
12 | (26) Furethidine; | ||||||
13 | (27) Hydroxpethidine; | ||||||
14 | (28) Ketobemidone; | ||||||
15 | (29) Levomoramide; | ||||||
16 | (30) Levophenacylmorphan; | ||||||
17 | (31) 3-Methylfentanyl
| ||||||
18 | (N-[3-methyl-1-(2-phenylethyl)-
| ||||||
19 | 4-piperidyl]-N-phenylpropanamide); | ||||||
20 | (31.1) 3-Methylthiofentanyl
| ||||||
21 | (N-[(3-methyl-1-(2-thienyl)ethyl-
| ||||||
22 | 4-piperidinyl]-N-phenylpropanamide); | ||||||
23 | (32) Morpheridine; | ||||||
24 | (33) Noracymethadol; | ||||||
25 | (34) Norlevorphanol; | ||||||
26 | (35) Normethadone; |
| |||||||
| |||||||
1 | (36) Norpipanone; | ||||||
2 | (36.1) Para-fluorofentanyl
| ||||||
3 | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
| ||||||
4 | 4-piperidinyl]propanamide); | ||||||
5 | (37) Phenadoxone; | ||||||
6 | (38) Phenampromide; | ||||||
7 | (39) Phenomorphan; | ||||||
8 | (40) Phenoperidine; | ||||||
9 | (41) Piritramide; | ||||||
10 | (42) Proheptazine; | ||||||
11 | (43) Properidine; | ||||||
12 | (44) Propiram; | ||||||
13 | (45) Racemoramide; | ||||||
14 | (45.1) Thiofentanyl
| ||||||
15 | (N-phenyl-N-[1-(2-thienyl)ethyl-
| ||||||
16 | 4-piperidinyl]-propanamide); | ||||||
17 | (46) Tilidine; | ||||||
18 | (47) Trimeperidine; | ||||||
19 | (48) Beta-hydroxy-3-methylfentanyl (other name:
| ||||||
20 | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| ||||||
21 | N-phenylpropanamide); | ||||||
22 | (49) Furanyl fentanyl (FU-F); | ||||||
23 | (50) Butyryl fentanyl; | ||||||
24 | (51) Valeryl fentanyl; | ||||||
25 | (52) Acetyl fentanyl; | ||||||
26 | (53) Beta-hydroxy-thiofentanyl; |
| |||||||
| |||||||
1 | (54) 3,4-dichloro-N-[2-
| ||||||
2 | (dimethylamino)cyclohexyl]-N-
| ||||||
3 | methylbenzamide (U-47700); | ||||||
4 | (55) 4-chloro-N-[1-[2-
| ||||||
5 | (4-nitrophenyl)ethyl]-2-piperidinylidene]-
| ||||||
6 | benzenesulfonamide (W-18); | ||||||
7 | (56) 4-chloro-N-[1-(2-phenylethyl)
| ||||||
8 | -2-piperidinylidene]-benzenesulfonamide (W-15); | ||||||
9 | (57) acrylfentanyl (acryloylfentanyl). | ||||||
10 | (c) Unless specifically excepted or unless listed in | ||||||
11 | another
schedule, any of the following opium derivatives, its | ||||||
12 | salts, isomers
and salts of isomers, whenever the existence of | ||||||
13 | such salts, isomers and
salts of isomers is possible within the | ||||||
14 | specific chemical designation: | ||||||
15 | (1) Acetorphine; | ||||||
16 | (2) Acetyldihydrocodeine; | ||||||
17 | (3) Benzylmorphine; | ||||||
18 | (4) Codeine methylbromide; | ||||||
19 | (5) Codeine-N-Oxide; | ||||||
20 | (6) Cyprenorphine; | ||||||
21 | (7) Desomorphine; | ||||||
22 | (8) Diacetyldihydromorphine (Dihydroheroin); | ||||||
23 | (9) Dihydromorphine; | ||||||
24 | (10) Drotebanol; | ||||||
25 | (11) Etorphine (except hydrochloride salt); | ||||||
26 | (12) Heroin; |
| |||||||
| |||||||
1 | (13) Hydromorphinol; | ||||||
2 | (14) Methyldesorphine; | ||||||
3 | (15) Methyldihydromorphine; | ||||||
4 | (16) Morphine methylbromide; | ||||||
5 | (17) Morphine methylsulfonate; | ||||||
6 | (18) Morphine-N-Oxide; | ||||||
7 | (19) Myrophine; | ||||||
8 | (20) Nicocodeine; | ||||||
9 | (21) Nicomorphine; | ||||||
10 | (22) Normorphine; | ||||||
11 | (23) Pholcodine; | ||||||
12 | (24) Thebacon. | ||||||
13 | (d) Unless specifically excepted or unless listed in | ||||||
14 | another
schedule, any material, compound, mixture, or | ||||||
15 | preparation which contains
any quantity of the following | ||||||
16 | hallucinogenic substances, or which
contains any of its salts, | ||||||
17 | isomers and salts of isomers, whenever the
existence of such | ||||||
18 | salts, isomers, and salts of isomers is possible
within the | ||||||
19 | specific chemical designation (for the purposes of this
| ||||||
20 | paragraph only, the term "isomer" includes the optical, | ||||||
21 | position and
geometric isomers): | ||||||
22 | (1) 3,4-methylenedioxyamphetamine
| ||||||
23 | (alpha-methyl,3,4-methylenedioxyphenethylamine,
| ||||||
24 | methylenedioxyamphetamine, MDA); | ||||||
25 | (1.1) Alpha-ethyltryptamine
| ||||||
26 | (some trade or other names: etryptamine;
|
| |||||||
| |||||||
1 | MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| ||||||
2 | 3-(2-aminobutyl)indole; a-ET; and AET); | ||||||
3 | (2) 3,4-methylenedioxymethamphetamine (MDMA); | ||||||
4 | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
| ||||||
5 | (also known as: N-ethyl-alpha-methyl-
| ||||||
6 | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
| ||||||
7 | and MDEA); | ||||||
8 | (2.2) N-Benzylpiperazine (BZP); | ||||||
9 | (2.2-1) Trifluoromethylphenylpiperazine (TFMPP); | ||||||
10 | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | ||||||
11 | (4) 3,4,5-trimethoxyamphetamine (TMA); | ||||||
12 | (5) (Blank); | ||||||
13 | (6) Diethyltryptamine (DET); | ||||||
14 | (7) Dimethyltryptamine (DMT); | ||||||
15 | (7.1) 5-Methoxy-diallyltryptamine; | ||||||
16 | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | ||||||
17 | (9) Ibogaine (some trade and other names:
| ||||||
18 | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| ||||||
19 | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
| ||||||
20 | indole; Tabernanthe iboga); | ||||||
21 | (10) Lysergic acid diethylamide; | ||||||
22 | (10.1) Salvinorin A; | ||||||
23 | (10.5) Salvia divinorum (meaning all parts of the plant | ||||||
24 | presently classified
botanically as Salvia divinorum, | ||||||
25 | whether growing or not, the
seeds thereof, any extract from | ||||||
26 | any part of that plant, and every compound,
manufacture, |
| |||||||
| |||||||
1 | salts, isomers, and salts of
isomers whenever the existence | ||||||
2 | of such salts, isomers, and salts of
isomers is possible | ||||||
3 | within the specific chemical designation, derivative, | ||||||
4 | mixture, or preparation of that plant, its
seeds or | ||||||
5 | extracts);
| ||||||
6 | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); | ||||||
7 | (12) Peyote (meaning all parts of the plant presently | ||||||
8 | classified
botanically as Lophophora williamsii
Lemaire, | ||||||
9 | whether growing or not, the
seeds thereof, any extract from | ||||||
10 | any part of that plant, and every compound,
manufacture, | ||||||
11 | salts, derivative, mixture, or preparation of that plant, | ||||||
12 | its
seeds or extracts); | ||||||
13 | (13) N-ethyl-3-piperidyl benzilate (JB 318); | ||||||
14 | (14) N-methyl-3-piperidyl benzilate; | ||||||
15 | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
| ||||||
16 | (also known as N-hydroxy-alpha-methyl-
| ||||||
17 | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); | ||||||
18 | (15) Parahexyl; some trade or other names:
| ||||||
19 | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
| ||||||
20 | dibenzo (b,d) pyran; Synhexyl; | ||||||
21 | (16) Psilocybin; | ||||||
22 | (17) Psilocyn; | ||||||
23 | (18) Alpha-methyltryptamine (AMT); | ||||||
24 | (19) 2,5-dimethoxyamphetamine
| ||||||
25 | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | ||||||
26 | (20) 4-bromo-2,5-dimethoxyamphetamine
|
| |||||||
| |||||||
1 | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| ||||||
2 | 4-bromo-2,5-DMA); | ||||||
3 | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| ||||||
4 | Some trade or other names: 2-(4-bromo-
| ||||||
5 | 2,5-dimethoxyphenyl)-1-aminoethane;
| ||||||
6 | alpha-desmethyl DOB, 2CB, Nexus; | ||||||
7 | (21) 4-methoxyamphetamine
| ||||||
8 | (4-methoxy-alpha-methylphenethylamine;
| ||||||
9 | paramethoxyamphetamine; PMA); | ||||||
10 | (22) (Blank); | ||||||
11 | (23) Ethylamine analog of phencyclidine.
| ||||||
12 | Some trade or other names:
| ||||||
13 | N-ethyl-1-phenylcyclohexylamine,
| ||||||
14 | (1-phenylcyclohexyl) ethylamine,
| ||||||
15 | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | ||||||
16 | (24) Pyrrolidine analog of phencyclidine. Some trade | ||||||
17 | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, | ||||||
18 | PHP; | ||||||
19 | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; | ||||||
20 | (26) 2,5-dimethoxy-4-ethylamphetamine
| ||||||
21 | (another name: DOET); | ||||||
22 | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
| ||||||
23 | (another name: TCPy); | ||||||
24 | (28) (Blank); | ||||||
25 | (29) Thiophene analog of phencyclidine (some trade
| ||||||
26 | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
|
| |||||||
| |||||||
1 | 2-thienyl analog of phencyclidine; TPCP; TCP); | ||||||
2 | (29.1) Benzothiophene analog of phencyclidine . Some | ||||||
3 | trade or other names: BTCP or benocyclidine; | ||||||
4 | (29.2) 3-Methoxyphencyclidine (3-MeO-PCP); | ||||||
5 | (30) Bufotenine (some trade or other names:
| ||||||
6 | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
| ||||||
7 | 3-(2-dimethylaminoethyl)-5-indolol;
| ||||||
8 | 5-hydroxy-N,N-dimethyltryptamine;
| ||||||
9 | N,N-dimethylserotonin; mappine); | ||||||
10 | (31) (Blank); | ||||||
11 | (32) (Blank); | ||||||
12 | (33) (Blank); | ||||||
13 | (34) (Blank); | ||||||
14 | (34.5) (Blank); | ||||||
15 | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | ||||||
16 | (2-methyloctan-2-yl)-6a,7, | ||||||
17 | 10,10a-tetrahydrobenzo[c]chromen-1-ol | ||||||
18 | Some trade or other names: HU-210; | ||||||
19 | (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- | ||||||
20 | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- | ||||||
21 | tetrahydrobenzo[c]chromen-1-ol, its isomers, | ||||||
22 | salts, and salts of isomers; Some trade or other | ||||||
23 | names: HU-210, Dexanabinol; | ||||||
24 | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | ||||||
25 | 6,6-dimethyl-3-(2-methyloctan-2-yl)- | ||||||
26 | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol |
| |||||||
| |||||||
1 | Some trade or other names: HU-211; | ||||||
2 | (37) (Blank); | ||||||
3 | (38) (Blank); | ||||||
4 | (39) (Blank); | ||||||
5 | (40) (Blank); | ||||||
6 | (41) (Blank); | ||||||
7 | (42) Any compound structurally derived from | ||||||
8 | 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane | ||||||
9 | by substitution at the nitrogen atom of the indole ring by | ||||||
10 | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | ||||||
11 | cycloalkylethyl, aryl halide, alkyl aryl halide, | ||||||
12 | 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
13 | 2-(4-morpholinyl)ethyl whether or not further substituted | ||||||
14 | in the indole ring to any extent, whether or not | ||||||
15 | substituted in the naphthyl ring to any extent. Examples of | ||||||
16 | this structural class include, but are not limited to, | ||||||
17 | JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185; | ||||||
18 | (43) Any compound structurally derived from | ||||||
19 | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen | ||||||
20 | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | ||||||
21 | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||||||
22 | halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
23 | 2-(4-morpholinyl)ethyl, whether or not further substituted | ||||||
24 | in the pyrrole ring to any extent, whether or not | ||||||
25 | substituted in the naphthyl ring to any extent. Examples of | ||||||
26 | this structural class include, but are not limited to, |
| |||||||
| |||||||
1 | JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; | ||||||
2 | (44) Any compound structurally derived from | ||||||
3 | 1-(1-naphthylmethyl)indene by substitution at the | ||||||
4 | 3-position of the indene ring by alkyl, haloalkyl, alkenyl, | ||||||
5 | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||||||
6 | halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
7 | 2-(4-morpholinyl)ethyl whether or not further substituted | ||||||
8 | in the indene ring to any extent, whether or not | ||||||
9 | substituted in the naphthyl ring to any extent. Examples of | ||||||
10 | this structural class include, but are not limited to, | ||||||
11 | JWH-176; | ||||||
12 | (45) Any compound structurally derived from | ||||||
13 | 3-phenylacetylindole by substitution at the nitrogen atom | ||||||
14 | of the indole ring with alkyl, haloalkyl, alkenyl, | ||||||
15 | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||||||
16 | halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
17 | 2-(4-morpholinyl)ethyl, whether or not further substituted | ||||||
18 | in the indole ring to any extent, whether or not | ||||||
19 | substituted in the phenyl ring to any extent. Examples of | ||||||
20 | this structural class include, but are not limited to, | ||||||
21 | JWH-167, JWH-250, JWH-251, and RCS-8; | ||||||
22 | (46) Any compound structurally derived from | ||||||
23 | 2-(3-hydroxycyclohexyl)phenol by substitution at the | ||||||
24 | 5-position of the phenolic ring by alkyl, haloalkyl, | ||||||
25 | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | ||||||
26 | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
| |||||||
| |||||||
1 | 2-(4-morpholinyl)ethyl, whether or not substituted in the | ||||||
2 | cyclohexyl ring to any extent. Examples of this structural | ||||||
3 | class include, but are not limited to, CP 47, 497 and its | ||||||
4 | C8 homologue (cannabicyclohexanol); | ||||||
5 | (46.1) Any compound structurally derived from | ||||||
6 | 3-(benzoyl) indole with substitution at the nitrogen atom | ||||||
7 | of the indole ring by an alkyl, haloalkyl, alkenyl, | ||||||
8 | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||||||
9 | halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
10 | 2-(4-morpholinyl)ethyl group whether or not further | ||||||
11 | substituted in the indole ring to any extent and whether or | ||||||
12 | not substituted in the phenyl ring to any extent. Examples | ||||||
13 | of this structural class include, but are not limited to, | ||||||
14 | AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and | ||||||
15 | RCS-4; | ||||||
16 | (47) (Blank); | ||||||
17 | (48) (Blank); | ||||||
18 | (49) (Blank); | ||||||
19 | (50) (Blank); | ||||||
20 | (51) (Blank); | ||||||
21 | (52) (Blank); | ||||||
22 | (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine . | ||||||
23 | Some trade or other names: 2C-T-7; | ||||||
24 | (53.1) 4-ethyl-2,5-dimethoxyphenethylamine . Some trade | ||||||
25 | or other names: 2C-E; | ||||||
26 | (53.2) 2,5-dimethoxy-4-methylphenethylamine . Some |
| |||||||
| |||||||
1 | trade or other names: 2C-D; | ||||||
2 | (53.3) 4-chloro-2,5-dimethoxyphenethylamine . Some | ||||||
3 | trade or other names: 2C-C; | ||||||
4 | (53.4) 4-iodo-2,5-dimethoxyphenethylamine . Some trade | ||||||
5 | or other names: 2C-I; | ||||||
6 | (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine . Some | ||||||
7 | trade or other names: 2C-T-2; | ||||||
8 | (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine . | ||||||
9 | Some trade or other names: 2C-T-4; | ||||||
10 | (53.7) 2,5-dimethoxyphenethylamine . Some trade or | ||||||
11 | other names: 2C-H; | ||||||
12 | (53.8) 2,5-dimethoxy-4-nitrophenethylamine . Some trade | ||||||
13 | or other names: 2C-N; | ||||||
14 | (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine . Some | ||||||
15 | trade or other names: 2C-P; | ||||||
16 | (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine . Some | ||||||
17 | trade or other names: 2C-G; | ||||||
18 | (53.11) The N-(2-methoxybenzyl) derivative of any 2C | ||||||
19 | phenethylamine referred to in subparagraphs (20.1), (53), | ||||||
20 | (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), | ||||||
21 | (53.8), (53.9), and (53.10) including, but not limited to, | ||||||
22 | 25I-NBOMe and 25C-NBOMe; | ||||||
23 | (54) 5-Methoxy-N,N-diisopropyltryptamine; | ||||||
24 | (55) (Blank); | ||||||
25 | (56) (Blank); | ||||||
26 | (57) (Blank); |
| |||||||
| |||||||
1 | (58) (Blank); | ||||||
2 | (59) 3-cyclopropoylindole with substitution at the | ||||||
3 | nitrogen atom of the indole ring by alkyl, haloalkyl, | ||||||
4 | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | ||||||
5 | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
6 | 2-(4-morpholinyl)ethyl, whether or not further substituted | ||||||
7 | on the indole ring to any extent, whether or not | ||||||
8 | substituted on the cyclopropyl ring to any extent: | ||||||
9 | including, but not limited to, XLR11, UR144, FUB-144; | ||||||
10 | (60) 3-adamantoylindole with substitution at the | ||||||
11 | nitrogen atom of the indole ring by alkyl, haloalkyl, | ||||||
12 | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | ||||||
13 | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
14 | 2-(4-morpholinyl)ethyl, whether or not further substituted | ||||||
15 | on the indole ring to any extent, whether or not | ||||||
16 | substituted on the adamantyl ring to any extent: including, | ||||||
17 | but not limited to, AB-001; | ||||||
18 | (61) N-(adamantyl)-indole-3-carboxamide with | ||||||
19 | substitution at the nitrogen atom of the indole ring by | ||||||
20 | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | ||||||
21 | cycloalkylethyl, aryl halide, alkyl aryl halide, | ||||||
22 | 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
23 | 2-(4-morpholinyl)ethyl, whether or not further substituted | ||||||
24 | on the indole ring to any extent, whether or not | ||||||
25 | substituted on the adamantyl ring to any extent: including, | ||||||
26 | but not limited to, APICA/2NE-1, STS-135; |
| |||||||
| |||||||
1 | (62) N-(adamantyl)-indazole-3-carboxamide with | ||||||
2 | substitution at a nitrogen atom of the indazole ring by | ||||||
3 | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | ||||||
4 | cycloalkylethyl, aryl halide, alkyl aryl halide, | ||||||
5 | 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
6 | 2-(4-morpholinyl)ethyl, whether or not further substituted | ||||||
7 | on the indazole ring to any extent, whether or not | ||||||
8 | substituted on the adamantyl ring to any extent: including, | ||||||
9 | but not limited to, AKB48, 5F-AKB48; | ||||||
10 | (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester | ||||||
11 | with substitution at the nitrogen atom of the indole ring | ||||||
12 | by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | ||||||
13 | cycloalkylethyl, aryl halide, alkyl aryl halide, | ||||||
14 | 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
15 | 2-(4-morpholinyl)ethyl, whether or not further substituted | ||||||
16 | on the indole ring to any extent, whether or not | ||||||
17 | substituted on the quinoline ring to any extent: including, | ||||||
18 | but not limited to, PB22, 5F-PB22, FUB-PB-22; | ||||||
19 | (64) 3-(1-naphthoyl)indazole with substitution at the | ||||||
20 | nitrogen atom of the indazole ring by alkyl, haloalkyl, | ||||||
21 | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | ||||||
22 | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
23 | 2-(4-morpholinyl)ethyl, whether or not further substituted | ||||||
24 | on the indazole ring to any extent, whether or not | ||||||
25 | substituted on the naphthyl ring to any extent: including, | ||||||
26 | but not limited to, THJ-018, THJ-2201; |
| |||||||
| |||||||
1 | (65) 2-(1-naphthoyl)benzimidazole with substitution at | ||||||
2 | the nitrogen atom of the benzimidazole ring by alkyl, | ||||||
3 | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | ||||||
4 | aryl halide, alkyl aryl halide, | ||||||
5 | 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
6 | 2-(4-morpholinyl)ethyl, whether or not further substituted | ||||||
7 | on the benzimidazole ring to any extent, whether or not | ||||||
8 | substituted on the naphthyl ring to any extent: including, | ||||||
9 | but not limited to, FUBIMINA; | ||||||
10 | (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole- | ||||||
11 | 3-carboxamide with substitution on the nitrogen atom of the | ||||||
12 | indazole ring by alkyl, haloalkyl, alkenyl, | ||||||
13 | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||||||
14 | halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
15 | 2-(4-morpholinyl)ethyl, whether or not further substituted | ||||||
16 | on the indazole ring to any extent: including, but not | ||||||
17 | limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA; | ||||||
18 | (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | ||||||
19 | indazole-3-carboxamide with substitution on the nitrogen | ||||||
20 | atom of the indazole ring by alkyl, haloalkyl, alkenyl, | ||||||
21 | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||||||
22 | halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
23 | 2-(4-morpholinyl)ethyl, whether or not further substituted | ||||||
24 | on the indazole ring to any extent: including, but not | ||||||
25 | limited to, ADB-PINACA, ADB-FUBINACA; | ||||||
26 | (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- |
| |||||||
| |||||||
1 | indole-3-carboxamide with substitution on the nitrogen | ||||||
2 | atom of the indole ring by alkyl, haloalkyl, alkenyl, | ||||||
3 | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||||||
4 | halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
5 | 2-(4-morpholinyl)ethyl, whether or not further substituted | ||||||
6 | on the indole ring to any extent: including, but not | ||||||
7 | limited to, ADBICA, 5F-ADBICA; | ||||||
8 | (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole- | ||||||
9 | 3-carboxamide with substitution on the nitrogen atom of the | ||||||
10 | indole ring by alkyl, haloalkyl, alkenyl, | ||||||
11 | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||||||
12 | halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
13 | 2-(4-morpholinyl)ethyl, whether or not further substituted | ||||||
14 | on the indole ring to any extent: including, but not | ||||||
15 | limited to, ABICA, 5F-ABICA; | ||||||
16 | (70) Methyl 2-(1H-indazole-3-carboxamido)-3- | ||||||
17 | methylbutanoate with substitution on the nitrogen atom of | ||||||
18 | the indazole ring by alkyl, haloalkyl, alkenyl, | ||||||
19 | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||||||
20 | halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
21 | 2-(4-morpholinyl)ethyl, whether or not further substituted | ||||||
22 | on the indazole ring to any extent: including, but not | ||||||
23 | limited to, AMB, 5F-AMB ; . | ||||||
24 | (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3- | ||||||
25 | dimethylbutanoate with substitution on the nitrogen
atom | ||||||
26 | of the indazole ring by alkyl, haloalkyl, alkenyl,
|
| |||||||
| |||||||
1 | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
aryl | ||||||
2 | halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
3 | 2-(4-morpholinyl)ethyl, whether or not further substituted
| ||||||
4 | on the indazole ring to any extent: including, but not
| ||||||
5 | limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; | ||||||
6 | (72) Methyl 2-(1H-indole-3-carboxamido)-3- | ||||||
7 | methylbutanoate with substitution on the nitrogen atom
of | ||||||
8 | the indole ring by alkyl, haloalkyl, alkenyl,
| ||||||
9 | cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl | ||||||
10 | halide, 1-(N-methyl-2-piperidinyl)methyl,
or | ||||||
11 | 2-(4-morpholinyl)ethyl, whether or not further
substituted | ||||||
12 | on the indazole ring to any extent:
including, but not | ||||||
13 | limited to, MMB018, MMB2201,
and AMB-CHMICA; | ||||||
14 | (73) Methyl 2-(1H-indole-3-carboxamido)-3,3- | ||||||
15 | dimethylbutanoate with substitution
on the nitrogen atom | ||||||
16 | of the indole ring by alkyl,
haloalkyl, alkenyl, | ||||||
17 | cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl | ||||||
18 | halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
19 | 2-(4-morpholinyl)ethyl,
whether or not further substituted | ||||||
20 | on the
indazole ring to any extent: including, but
not | ||||||
21 | limited to, MDMB-CHMICA; | ||||||
22 | (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H- | ||||||
23 | indazole-3-carboxamide with
substitution on the nitrogen | ||||||
24 | atom of the indazole
ring by alkyl, haloalkyl, alkenyl, | ||||||
25 | cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl | ||||||
26 | halide,
1-(N-methyl-2-piperidinyl)methyl, or |
| |||||||
| |||||||
1 | 2-(4-morpholinyl)ethyl, whether or not further
substituted | ||||||
2 | on the indazole ring to any
extent: including, but not | ||||||
3 | limited to, APP-CHMINACA,
5-fluoro-APP-PINACA; | ||||||
4 | (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole- | ||||||
5 | 3-carboxamide with substitution on
the nitrogen atom of the | ||||||
6 | indole ring by alkyl,
haloalkyl, alkenyl, | ||||||
7 | cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl | ||||||
8 | halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
9 | 2-(4-morpholinyl)ethyl,
whether or not further substituted | ||||||
10 | on the indazole
ring to any extent: including, but not | ||||||
11 | limited to,
APP-PICA and 5-fluoro-APP-PICA; | ||||||
12 | (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name | ||||||
13 | 4-AcO-DMT; | ||||||
14 | (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade | ||||||
15 | name 5-MeO-MIPT; | ||||||
16 | (78) 4-hydroxy Diethyltryptamine (4-HO-DET); | ||||||
17 | (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); | ||||||
18 | (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); | ||||||
19 | (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
| ||||||
20 | (4-HO-MiPT); | ||||||
21 | (82) Fluorophenylpiperazine; | ||||||
22 | (83) Methoxetamine; | ||||||
23 | (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso- | ||||||
24 | ethcathinone). | ||||||
25 | (e) Unless specifically excepted or unless listed in | ||||||
26 | another
schedule, any material, compound, mixture, or |
| |||||||
| |||||||
1 | preparation which contains
any quantity of the following | ||||||
2 | substances having a depressant effect on
the central nervous | ||||||
3 | system, including its salts, isomers, and salts of
isomers | ||||||
4 | whenever the existence of such salts, isomers, and salts of
| ||||||
5 | isomers is possible within the specific chemical designation: | ||||||
6 | (1) mecloqualone; | ||||||
7 | (2) methaqualone; and | ||||||
8 | (3) gamma hydroxybutyric acid. | ||||||
9 | (f) Unless specifically excepted or unless listed in | ||||||
10 | another schedule,
any material, compound, mixture, or | ||||||
11 | preparation which contains any quantity
of the following | ||||||
12 | substances having a stimulant effect on the central nervous
| ||||||
13 | system, including its salts, isomers, and salts of isomers: | ||||||
14 | (1) Fenethylline; | ||||||
15 | (2) N-ethylamphetamine; | ||||||
16 | (3) Aminorex (some other names:
| ||||||
17 | 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| ||||||
18 | 4-5-dihydro-5-phenyl-2-oxazolamine) and its
| ||||||
19 | salts, optical isomers, and salts of optical isomers; | ||||||
20 | (4) Methcathinone (some other names:
| ||||||
21 | 2-methylamino-1-phenylpropan-1-one;
| ||||||
22 | Ephedrone; 2-(methylamino)-propiophenone;
| ||||||
23 | alpha-(methylamino)propiophenone; N-methylcathinone;
| ||||||
24 | methycathinone; Monomethylpropion; UR 1431) and its
| ||||||
25 | salts, optical isomers, and salts of optical isomers; | ||||||
26 | (5) Cathinone (some trade or other names:
|
| |||||||
| |||||||
1 | 2-aminopropiophenone; alpha-aminopropiophenone;
| ||||||
2 | 2-amino-1-phenyl-propanone; norephedrone); | ||||||
3 | (6) N,N-dimethylamphetamine (also known as:
| ||||||
4 | N,N-alpha-trimethyl-benzeneethanamine;
| ||||||
5 | N,N-alpha-trimethylphenethylamine); | ||||||
6 | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
| ||||||
7 | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | ||||||
8 | (8) 3,4-Methylenedioxypyrovalerone (MDPV); | ||||||
9 | (9) Halogenated amphetamines and
| ||||||
10 | methamphetamines - any compound derived from either
| ||||||
11 | amphetamine or methamphetamine through the substitution
| ||||||
12 | of a halogen on the phenyl ring, including, but not
| ||||||
13 | limited to, 2-fluoroamphetamine, 3-
| ||||||
14 | fluoroamphetamine and 4-fluoroamphetamine; | ||||||
15 | (10) Aminopropylbenzofuran (APB):
| ||||||
16 | including 4-(2-Aminopropyl) benzofuran, 5-
| ||||||
17 | (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
| ||||||
18 | benzofuran, and 7-(2-Aminopropyl) benzofuran; | ||||||
19 | (11) Aminopropyldihydrobenzofuran (APDB):
| ||||||
20 | including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
| ||||||
21 | 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
| ||||||
22 | 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
| ||||||
23 | and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; | ||||||
24 | (12) Methylaminopropylbenzofuran
| ||||||
25 | (MAPB): including 4-(2-methylaminopropyl)
| ||||||
26 | benzofuran, 5-(2-methylaminopropyl)benzofuran,
|
| |||||||
| |||||||
1 | 6-(2-methylaminopropyl)benzofuran
| ||||||
2 | and 7-(2-methylaminopropyl)benzofuran. | ||||||
3 | (g) Temporary listing of substances subject to emergency | ||||||
4 | scheduling.
Any material, compound, mixture, or preparation | ||||||
5 | that contains any quantity
of the following substances: | ||||||
6 | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
| ||||||
7 | (benzylfentanyl), its optical isomers, isomers, salts,
and | ||||||
8 | salts of isomers; | ||||||
9 | (2) N-[1(2-thienyl)
methyl-4-piperidyl]-N- | ||||||
10 | phenylpropanamide (thenylfentanyl),
its optical isomers, | ||||||
11 | salts, and salts of isomers. | ||||||
12 | (h) Synthetic cathinones. Unless specifically excepted, | ||||||
13 | any chemical compound which is not approved by the United | ||||||
14 | States Food and Drug Administration or, if approved, is not | ||||||
15 | dispensed or possessed in accordance with State or federal law, | ||||||
16 | not including bupropion, structurally derived from | ||||||
17 | 2-aminopropan-1-one by substitution at the 1-position with | ||||||
18 | either phenyl, naphthyl, or thiophene ring systems, whether or | ||||||
19 | not the compound is further modified in one or more of the | ||||||
20 | following ways: | ||||||
21 | (1) by substitution in the ring system to any extent | ||||||
22 | with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or | ||||||
23 | halide substituents, whether or not further substituted in | ||||||
24 | the ring system by one or more other univalent | ||||||
25 | substituents. Examples of this class include, but are not | ||||||
26 | limited to, 3,4-Methylenedioxycathinone (bk-MDA); |
| |||||||
| |||||||
1 | (2) by substitution at the 3-position with an acyclic | ||||||
2 | alkyl substituent. Examples of this class include, but are | ||||||
3 | not limited to, 2-methylamino-1-phenylbutan-1-one | ||||||
4 | (buphedrone); or | ||||||
5 | (3) by substitution at the 2-amino nitrogen atom with | ||||||
6 | alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by | ||||||
7 | inclusion of the 2-amino nitrogen atom in a cyclic | ||||||
8 | structure. Examples of this class include, but are not | ||||||
9 | limited to, Dimethylcathinone, Ethcathinone, and | ||||||
10 | a-Pyrrolidinopropiophenone (a-PPP) ; or . | ||||||
11 | Any other synthetic cathinone which is not approved by the | ||||||
12 | United States Food and Drug Administration or, if approved, is | ||||||
13 | not dispensed or possessed in accordance with State or federal | ||||||
14 | law. | ||||||
15 | (i) Synthetic cannabinoids or piperazines. Any synthetic | ||||||
16 | cannabinoid or piperazine which is not approved by the United | ||||||
17 | States Food and Drug Administration or, if approved, which is | ||||||
18 | not dispensed or possessed in accordance with State and federal | ||||||
19 | law. | ||||||
20 | (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17; | ||||||
21 | 100-368, eff. 1-1-18; revised 10-5-17.)".
|